Overview

Comparison the Safety and Pharmacokinetic Characteristics of DWP422 25 mg With Those of ENBREL 25MG PFS INJ. After Subcutaneous Injection in Healthy Male Volunteers

Status:
Unknown status

Trial end date:
2013-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study was to compare the safety and pharmacokinetic characteristics of DWP422 25 mg with those of ENBREL 25MG PFS INJ. after subcutaneous injection in healthy male volunteers.

Phase:

Phase 1

Details

Lead Sponsor:

Daewoong Pharmaceutical Co. LTD.

Treatments:

Etanercept